VENTAC PARTNERS IS A DEDICATED LIFE SCIENCE CONSULTING FIRM WITH OFFICES IN EUROPE, USA AND ASIA.
Ventac Partners has a strong track record in founding new innovative companies, strategic and operational market and product analysis, intellectual property development, fund raising, licensing, M&A and strategy consulting.
All partners are experienced executives from pharma, biotech and medtech companies, and preclinical, clinical and regulatory, legal and intellectual property experts with extensive backgrounds in successfully starting, growing and expanding international life science companies.
Latest News November, 2013 |
Avexxin AS has completed an additional series B round financing facilitated by Sparebank1 SMN
Markets, Norway, see Portfolio News.
November, 2013 |
APIM Therapeutics has completed a new financing round by existing investors Norsk Innovasjons-kapital III, Sarsia Seed, Birk Venture and Ro Invest, see
VP News.April, 2013 |
Ventac Partners and Norwegian University of Science and Technology (NTNU) celebrate 10-year anniversary, see
VP News.February, 2013 |
A Board of Swiss investors selects Zestagen as #1 biotech company to invest in on behalf of the prestigious Swiss economic review
Avexxin receives regulatory approval to continue its phase I/IIa clinical trial with its lead compound AVX-001.